These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23951230)

  • 21. Inhibiting Plasmodium cytochrome bc1: a complex issue.
    Barton V; Fisher N; Biagini GA; Ward SA; O'Neill PM
    Curr Opin Chem Biol; 2010 Aug; 14(4):440-6. PubMed ID: 20570550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria.
    Biagini GA; Fisher N; Shone AE; Mubaraki MA; Srivastava A; Hill A; Antoine T; Warman AJ; Davies J; Pidathala C; Amewu RK; Leung SC; Sharma R; Gibbons P; Hong DW; Pacorel B; Lawrenson AS; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Stocks PA; Nixon GL; Chadwick J; Hemingway J; Delves MJ; Sinden RE; Zeeman AM; Kocken CH; Berry NG; O'Neill PM; Ward SA
    Proc Natl Acad Sci U S A; 2012 May; 109(21):8298-303. PubMed ID: 22566611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
    McConnell EV; Bruzual I; Pou S; Winter R; Dodean RA; Smilkstein MJ; Krollenbrock A; Nilsen A; Zakharov LN; Riscoe MK; Doggett JS
    ACS Infect Dis; 2018 Nov; 4(11):1574-1584. PubMed ID: 30117728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
    White J; Dhingra SK; Deng X; El Mazouni F; Lee MCS; Afanador GA; Lawong A; Tomchick DR; Ng CL; Bath J; Rathod PK; Fidock DA; Phillips MA
    ACS Infect Dis; 2019 Jan; 5(1):90-101. PubMed ID: 30375858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
    Leung SC; Gibbons P; Amewu R; Nixon GL; Pidathala C; Hong WD; Pacorel B; Berry NG; Sharma R; Stocks PA; Srivastava A; Shone AE; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Hill A; Fisher NE; Warman AJ; Biagini GA; Ward SA; O'Neill PM
    J Med Chem; 2012 Mar; 55(5):1844-57. PubMed ID: 22364417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods.
    Akhoon BA; Singh KP; Varshney M; Gupta SK; Shukla Y; Gupta SK
    PLoS One; 2014; 9(10):e110041. PubMed ID: 25334024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decoding the Molecular Effects of Atovaquone Linked Resistant Mutations on
    Chebon-Bore L; Sanyanga TA; Manyumwa CV; Khairallah A; Tastan Bishop Ö
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.
    Ke H; Ganesan SM; Dass S; Morrisey JM; Pou S; Nilsen A; Riscoe MK; Mather MW; Vaidya AB
    PLoS One; 2019; 14(4):e0214023. PubMed ID: 30964863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.
    Kessl JJ; Ha KH; Merritt AK; Lange BB; Hill P; Meunier B; Meshnick SR; Trumpower BL
    J Biol Chem; 2005 Apr; 280(17):17142-8. PubMed ID: 15718226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis.
    Basco LK
    Am J Trop Med Hyg; 2003 Aug; 69(2):179-83. PubMed ID: 14506774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia.
    Gebru T; Hailu A; Kremsner PG; Kun JF; Grobusch MP
    Malar J; 2006 Nov; 5():112. PubMed ID: 17118179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical studies of membrane bound Plasmodium falciparum mitochondrial L-malate:quinone oxidoreductase, a potential drug target.
    Hartuti ED; Inaoka DK; Komatsuya K; Miyazaki Y; Miller RJ; Xinying W; Sadikin M; Prabandari EE; Waluyo D; Kuroda M; Amalia E; Matsuo Y; Nugroho NB; Saimoto H; Pramisandi A; Watanabe YI; Mori M; Shiomi K; Balogun EO; Shiba T; Harada S; Nozaki T; Kita K
    Biochim Biophys Acta Bioenerg; 2018 Mar; 1859(3):191-200. PubMed ID: 29269266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinolone-3-diarylethers: a new class of antimalarial drug.
    Nilsen A; LaCrue AN; White KL; Forquer IP; Cross RM; Marfurt J; Mather MW; Delves MJ; Shackleford DM; Saenz FE; Morrisey JM; Steuten J; Mutka T; Li Y; Wirjanata G; Ryan E; Duffy S; Kelly JX; Sebayang BF; Zeeman AM; Noviyanti R; Sinden RE; Kocken CHM; Price RN; Avery VM; Angulo-Barturen I; Jiménez-Díaz MB; Ferrer S; Herreros E; Sanz LM; Gamo FJ; Bathurst I; Burrows JN; Siegl P; Guy RK; Winter RW; Vaidya AB; Charman SA; Kyle DE; Manetsch R; Riscoe MK
    Sci Transl Med; 2013 Mar; 5(177):177ra37. PubMed ID: 23515079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the Ubiquinol-Reduction (Q
    Amporndanai K; Pinthong N; O'Neill PM; Hong WD; Amewu RK; Pidathala C; Berry NG; Leung SC; Ward SA; Biagini GA; Hasnain SS; Antonyuk SV
    Biology (Basel); 2022 Jul; 11(8):. PubMed ID: 35892964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atovaquone-statine "double-drugs" with high antiplasmodial activity.
    Romeo S; Parapini S; Dell'Agli M; Vaiana N; Magrone P; Galli G; Sparatore A; Taramelli D; Bosisio E
    ChemMedChem; 2008 Mar; 3(3):418-20. PubMed ID: 18064618
    [No Abstract]   [Full Text] [Related]  

  • 36. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum.
    Peters JM; Chen N; Gatton M; Korsinczky M; Fowler EV; Manzetti S; Saul A; Cheng Q
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2435-41. PubMed ID: 12121915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.
    Khositnithikul R; Tan-Ariya P; Mungthin M
    Malar J; 2008 Jan; 7():23. PubMed ID: 18226262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations.
    Musset L; Bouchaud O; Matheron S; Massias L; Le Bras J
    Microbes Infect; 2006 Sep; 8(11):2599-604. PubMed ID: 16962361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
    Ouji M; Nguyen M; Mustière R; Jimenez T; Augereau JM; Benoit-Vical F; Deraeve C
    Bioorg Med Chem Lett; 2021 May; 39():127884. PubMed ID: 33636304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights into cytochrome bc1 complex binding mode of antimalarial 2-hydroxy-1,4-naphthoquinones through molecular modelling.
    Sodero AC; Abrahim-Vieira B; Torres PH; Pascutti PG; Garcia CR; Ferreira VF; Rocha DR; Ferreira SB; Silva FP
    Mem Inst Oswaldo Cruz; 2017 Apr; 112(4):299-308. PubMed ID: 28327793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.